This document provides guidelines for the evaluation of medicinal products in juvenile idiopathic arthritis. It addresses specific issues related to the design of clinical studies, extrapolation of efficacy from other age groups and corresponding arthritis diagnoses, and assessment of disease activity.
Keywords: Juvenile idiopathic arthritis, systemic juvenile idiopatic arthritis, oligoarthritis, polyarthritis, enthesitis related arthritis, extrapolation
Current effective version
Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - Revision 2
Juvenile idiopathic arthritis (JIA) is currently grouped in multiple categories some of which have counterparts in the more frequent adult diseases of rheumatoid arthritis (RA), axial spondyloarthritis and psoriatic arthritis (PsA) although with considerable differences in phenotype at different ages. Since the Paediatric Regulation came into force, several paediatric investigation plans (PIPs) for new and authorised treatments in adults have been evaluated by the Paediatric Committee (PDCO).
English (EN) (197.53 KB - PDF)
Document history - Revision 2 (current version)
Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - Revision 2
Juvenile idiopathic arthritis (JIA) is currently grouped in multiple categories some of which have counterparts in the more frequent adult diseases of rheumatoid arthritis (RA), axial spondyloarthritis and psoriatic arthritis (PsA) although with considerable differences in phenotype at different ages. Since the Paediatric Regulation came into force, several paediatric investigation plans (PIPs) for new and authorised treatments in adults have been evaluated by the Paediatric Committee (PDCO).
English (EN) (197.53 KB - PDF)
Overview of comments received on the 'Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis'
English (EN) (541.97 KB - PDF)
Draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - Revision 2
The proposed guideline will replace the guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis (CPMP/EWP/422/04)
English (EN) (219.49 KB - PDF)
Concept paper on the need for revision of the guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis
The current guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis (JIA) was adopted in 2006. Since then there have been major advances in the understanding of the pathophysiology of JIA subtypes, along with the introduction of new treatments including biological therapies. An update of the current JIA guideline is required to reflect these recent advances.
English (EN) (74.33 KB - PDF)
Document history - First version
Guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version
English (EN) (116.21 KB - PDF)
Overview of comments received on draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version
English (EN) (161.26 KB - PDF)
Draft guideline on clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis - First version
English (EN) (95.34 KB - PDF)
Related content
- Clinical efficacy and safety: rheumatology/musculoskeletal system
- Directive 2001/83/EC
- Choice of a non-inferiority margin
- Clinical development of fixed combination medicinal products
- Clinical trials in small populations
- Extrapolation of efficacy and safety in medicine development
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E10 Choice of control group in clinical trials
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- Investigation of drug interactions
- Methodological issues in confirmatory clinical trials planned with an adaptive design
- Pharmaceutical development of medicines for paediatric use
- Role of pharmacokinetics in the development of medicinal products in the paediatric population